JP2022546414A - Perk阻害ピロロピリミジン化合物 - Google Patents

Perk阻害ピロロピリミジン化合物 Download PDF

Info

Publication number
JP2022546414A
JP2022546414A JP2022513164A JP2022513164A JP2022546414A JP 2022546414 A JP2022546414 A JP 2022546414A JP 2022513164 A JP2022513164 A JP 2022513164A JP 2022513164 A JP2022513164 A JP 2022513164A JP 2022546414 A JP2022546414 A JP 2022546414A
Authority
JP
Japan
Prior art keywords
amino
pyrrolo
pyrimidin
alkyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546414A5 (cg-RX-API-DMAC7.html
Inventor
マーク ジェイ. マルヴィヒル,
アン-フー リー,
マシュー デイビッド サーマン,
Original Assignee
ヒベルセル, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヒベルセル, インコーポレイテッド filed Critical ヒベルセル, インコーポレイテッド
Publication of JP2022546414A publication Critical patent/JP2022546414A/ja
Publication of JP2022546414A5 publication Critical patent/JP2022546414A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022513164A 2019-08-29 2020-08-28 Perk阻害ピロロピリミジン化合物 Pending JP2022546414A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962893528P 2019-08-29 2019-08-29
US62/893,528 2019-08-29
PCT/US2020/048621 WO2021041975A1 (en) 2019-08-29 2020-08-28 Perk inhibiting pyrrolopyrimidine compounds

Publications (2)

Publication Number Publication Date
JP2022546414A true JP2022546414A (ja) 2022-11-04
JP2022546414A5 JP2022546414A5 (cg-RX-API-DMAC7.html) 2023-08-28

Family

ID=72470610

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022513164A Pending JP2022546414A (ja) 2019-08-29 2020-08-28 Perk阻害ピロロピリミジン化合物

Country Status (12)

Country Link
US (1) US20220356186A1 (cg-RX-API-DMAC7.html)
EP (1) EP4021908A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022546414A (cg-RX-API-DMAC7.html)
KR (1) KR20220066290A (cg-RX-API-DMAC7.html)
CN (1) CN114710956A (cg-RX-API-DMAC7.html)
AU (1) AU2020336975A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022003584A2 (cg-RX-API-DMAC7.html)
CA (1) CA3152508A1 (cg-RX-API-DMAC7.html)
IL (1) IL290889A (cg-RX-API-DMAC7.html)
MX (1) MX2022002446A (cg-RX-API-DMAC7.html)
PH (1) PH12022550491A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021041975A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021041973A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting compounds
CA3182276A1 (en) 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
CN117597346A (zh) * 2021-04-05 2024-02-23 哈利亚治疗公司 Nek7抑制剂
JP2024513227A (ja) * 2021-04-05 2024-03-22 ハリア・セラピューティクス・インコーポレイテッド Nek7阻害剤
US20240287081A1 (en) * 2021-06-09 2024-08-29 Icahn School Of Medicine At Mount Sinai Perfluoroalkane substituted pyrazolo[3,4-d]pyrimidin and pyrrolo[2,3-d]pyrimidin compounds and uses thereof
US20250000859A1 (en) 2021-08-25 2025-01-02 Alesta Therapeutics BV Use of gcn2 inhibitors in treating cancer
GB202407386D0 (en) 2024-05-24 2024-07-10 Apollo Ap45 Ltd 1H-pyrazolo(4,3-D)pyrimidine derivatives

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017046739A1 (en) * 2015-09-15 2017-03-23 Glaxosmithkline Intellectual Property (No.2) Limited Imidazolidinone derivatives as inhibitors of perk
JP2018527412A (ja) * 2015-09-15 2018-09-20 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Perk阻害剤としての1−フェニルピロリジン−2−オン誘導体
WO2018194885A1 (en) * 2017-04-18 2018-10-25 Eli Lilly And Company Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903297A (en) 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
BR9808281A (pt) * 1997-03-19 2000-05-16 Basf Ag Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto
US7863444B2 (en) * 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
EP3067356B1 (en) * 2013-11-08 2018-07-04 ONO Pharmaceutical Co., Ltd. Pyrrolo pyrimidine derivative
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
WO2016085160A2 (ko) * 2014-11-28 2016-06-02 (주)네오팜 발모촉진용 또는 탈모방지용 조성물
GB201508747D0 (en) * 2015-05-21 2015-07-01 Univ Edinburgh Compounds
EP3481831B1 (en) * 2016-07-07 2023-09-06 Daewoong Pharmaceutical Co., Ltd. 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017046739A1 (en) * 2015-09-15 2017-03-23 Glaxosmithkline Intellectual Property (No.2) Limited Imidazolidinone derivatives as inhibitors of perk
JP2018527412A (ja) * 2015-09-15 2018-09-20 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Perk阻害剤としての1−フェニルピロリジン−2−オン誘導体
WO2018194885A1 (en) * 2017-04-18 2018-10-25 Eli Lilly And Company Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds

Also Published As

Publication number Publication date
KR20220066290A (ko) 2022-05-24
IL290889A (en) 2022-04-01
BR112022003584A2 (pt) 2022-05-24
CA3152508A1 (en) 2021-03-04
WO2021041975A1 (en) 2021-03-04
AU2020336975A1 (en) 2022-03-31
PH12022550491A1 (en) 2023-02-06
CN114710956A (zh) 2022-07-05
US20220356186A1 (en) 2022-11-10
EP4021908A1 (en) 2022-07-06
MX2022002446A (es) 2022-06-02

Similar Documents

Publication Publication Date Title
CN113453681B (zh) 经取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物及使用它们的治疗方法
US20220356186A1 (en) Perk inhibiting pyrrolopyrimidine compounds
ES2831832T3 (es) Compuestos de indol ciano-sustituidos y usos de los mismos como inhibidores de LSD1
US12473296B2 (en) Perk inhibiting compounds
US10538502B2 (en) Tricyclic spiro compound
TWI746562B (zh) 磺醯胺化合物或其鹽
WO2021041976A1 (en) Perk inhibiting indolinyl compounds
US12331054B2 (en) Perk inhibiting imidazolopyrazine compounds
CN108601781A (zh) 作为检测点激酶1(chk1)抑制剂的3,5-二取代吡唑及其制备及应用
CN104684899A (zh) 取代的磺酰胺化合物
JP2014520860A (ja) タンキラーゼ阻害剤として使用するための4−オキソ−3,5,7,8−テトラヒドロ−4H−ピラノ{4,3−d}ピルミニジニル化合物
US10584116B2 (en) Heterocyclic sulfonamide derivative and medicine containing same
CN110156674A (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物
CN114555597B (zh) 异柠檬酸脱氢酶(idh)抑制剂
US9901571B2 (en) Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists
TWI724995B (zh) 作為生長激素釋放肽受體激動劑之絲胺酸衍生物
WO2024255743A9 (en) Inhibitors of trek (twik related k+ channels) channel function
WO2019141095A1 (zh) 脒类和胍类衍生物、其制备方法及其在医药上的应用
HK1240210B (en) Amide derivative, and preparation method and pharmaceutical use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230818

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241224